EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Lunit Inc. (328130) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Lunit Inc. KRW 1,238, price KRW 10,570, upside -88.3%, quality 22 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR

LI Thin data Jul 21, 2026

Lunit Inc.

328130 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 1,238 KRW · Strongly overvalued (−88.3%)
!Quality 22/100
!Expensive Growth (revenue 5y +125.4 %/yr)
!Loss-making · -76.3% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (2/8)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch Lunit Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

56,074 KRW 4,252 KRW Fair Value 1,238 KRW Jul 2022 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.

How to read this chart

50‑month range 4,252 KRW – 56,074 KRW · fair‑value band 923.82 KRW – 1,848 KRW · the 10,570 KRW price screens above the 1,238 KRW fair value. Dashed = 300-day average. As of Jul 21, 2026.

Follow Lunit in your weekly email

Every Wednesday you see whether Lunit is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer.

Show more

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; and with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.

Stock analysis

Lunit Inc. (328130) currently trades at 10,570 KRW, while our model-based Fair Value estimate is 1,238 KRW, 88.3% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 923.82 KRW (bear) to 1,848 KRW (bull), the price of 10,570 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Lunit Inc. reported revenue of 83.1B KRW in FY2025 versus 6.6B KRW in FY2021, a compound +88.1%/yr. Reported net income was −47.4B KRW in FY2025.

Key figures

Market cap 747B KRW (≈ $556M) · P/S ratio 8.50 · Net margin −57.0% · Return on equity −45.3% · Return on assets (EBIT) −30.9% · Operating margin −56.8% · Revenue (TTM) 87.9B KRW · Revenue growth (YoY) +24.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (low confidence).

What moves the price

The share trades about 54% below its 52-week high and 29% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −88%, 328130 screens richer than that median.

Fair Value models

Bear 923.82 KRW Fair Value 1,238 KRW Bull 1,848 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 923.82 KRW 1,238 KRW 1,848 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 923.82 KRW 1,238 KRW 1,848 KRW 54

Open the full fair value analysis →

Notify me when 328130 reaches fair value

Put 328130 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 22/100

Of which business quality 25 · Market factors (momentum, volatility) 16

Profitability 10
Margins and returns on capital today
Quality Growth 89
Are margins and returns improving?
Cashflow 15
Earnings quality: real cash, not paper profit
Fin. Strength 32
Balance sheet, leverage, solvency risk
Investment 16
Disciplined investing over empire-building
Low Volatility 24
Calm price path (market factor)
Momentum 14
Price trend over the last 3–12 months (market factor)
52W Momentum 8
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+53.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+81.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+125.4%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+173.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,465.0% (2020) → −100.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

328130 screens overvalued: fair value 88% below the price. Compare with Veeva Systems Inc →

Compare Lunit Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 128 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside −88.3% · Bottom 25%
Profitability
Return on assets −11.8% · Bottom 25%
Net margin (TTM) −76.3% · Bottom 25%
Operating margin (TTM) −56.8% · Bottom 25%
Growth and dividend
Revenue growth 24.7% · Top 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 41
PAST (return on equity)0 · sector 8
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 44

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $278.57 $306.43 +10%
Pro Medicus Limited PME A$161.00 A$84.62 −47%
BrightSpring Health Services, Inc BTSG $56.54 $25.86 −54%
Hinge Health, Inc HNGE $95.57 $51.25 −46%
HealthEquity, Inc HQY $88.44 $97.28 +10%
Waystar Holding WAY $24.70 $27.17 +10%
Doximity, Inc DOCS $26.35 $31.41 +19%
XtalPi Holdings 2228 HK$7.75 HK$1.50 −81%
Inventurus Knowledge Solutions Limited IKS ₹1,779 ₹1,883 +6%
Privia Health Group PRVA $19.62 $5.02 −74%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lunit Inc. · Fair Value
1,238 KRW −88%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Lunit Inc. Fair Value". https://www.fairvalue-calculator.com/stock/328130

Frequently asked questions

Is Lunit Inc. (328130) overvalued or undervalued?
As of Jul 21, 2026, our model estimates a fair value of 1,238 KRW versus a price of 10,570 KRW, about −88% upside (overvalued).
What is the fair value of 328130?
Our model-based fair value for Lunit Inc. is 1,238 KRW (as of Jul 21, 2026), built from audited fundamentals. The current price: 10,570 KRW.
What is the quality score of 328130?
Lunit Inc. has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lunit Inc. (328130)?
Our model-based price target is the fair value of 1,238 KRW (as of Jul 21, 2026) from 1 valuation models. Cautious scenario 923.82 KRW, optimistic scenario 1,848 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Lunit Inc. stock forecast for 2026?
Our models put fair value at 1,238 KRW, about −88% upside versus a price of 10,570 KRW (overvalued). Cautious scenario 923.82 KRW, optimistic scenario 1,848 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Lunit Inc. (328130)?
Lunit Inc. reported trailing-twelve-month revenue of about 87.9B KRW (latest available figure, as of Jul 21, 2026).
What is the intrinsic value of Lunit Inc. (328130)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lunit Inc. it is 1,238 KRW per share (as of Jul 21, 2026), against a price of 10,570 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Lunit Inc. stock overvalued or undervalued in 2026?
As of Jul 21, 2026, 328130 trades above its calculated fair value: price 10,570 KRW, fair value 1,238 KRW, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 328130?
No. The price is what the market pays today (10,570 KRW); the fair value is what the company's own numbers justify (1,238 KRW). For Lunit Inc. the two are 9,332 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Lunit Inc. worth?
The market values Lunit Inc. at about 747B KRW (market capitalisation, as of Jul 21, 2026). Per share that is 10,570 KRW; our models calculate a fair value of 1,238 KRW per share.
What do the bullish and bearish scenarios say about 328130?
Our models span a range for Lunit Inc.: cautious scenario 923.82 KRW, base 1,238 KRW, optimistic 1,848 KRW per share (as of Jul 21, 2026, price 10,570 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Lunit Inc. (328130)?
Balance-sheet figures for Lunit Inc. (as of Jul 21, 2026): return on equity −45.3%. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is 328130 from its 52-week high?
Lunit Inc. trades at 10,570 KRW, about 54% below its 52-week high of 22,934 KRW and 29% above the low of 8,210 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 1,238 KRW is for.
Which stocks are comparable to Lunit Inc.?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lunit Inc. stock attractive at the current price?
The data as of Jul 21, 2026: price 10,570 KRW, calculated fair value 1,238 KRW (−88%), Quality Score 22/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 328130 calculated?
We run Lunit Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,238 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Lunit Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lunit Inc. (328130)?
The closing price on Oct 2, 2026 was 10,570 KRW. Our model-based fair value is 1,238 KRW, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lunit Inc. right now?
The price sits above even our optimistic bull case (1,848 KRW). The favourable scenario is already priced in. Weak quality (22/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (923.82 KRW to 1,848 KRW) leaves room in how you read the outcome.

Key figures of Lunit Inc.

How large is the market capitalisation of Lunit Inc. (328130)?
The market capitalisation of Lunit Inc. is 747B KRW (≈ $556M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lunit Inc. (328130)?
The price-to-sales ratio of Lunit Inc. is 8.50 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Lunit Inc. (328130)?
The net margin of Lunit Inc. is −57.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lunit Inc. (328130)?
The return on equity (ROE) of Lunit Inc. is −45.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lunit Inc. (328130)?
On an EBIT basis the return on assets of Lunit Inc. is −30.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lunit Inc. (328130)?
The operating margin of Lunit Inc. is −56.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lunit Inc. (328130)?
Revenue at Lunit Inc. is growing +24.7% versus a year earlier (3y avg +81.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Lunit Inc. (328130) generate?
The free cash flow of Lunit Inc. is −64.8B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Lunit Inc. (328130) carry?
The net debt of Lunit Inc. is 79.3B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Lunit Inc. in the live analysis

One click puts Lunit Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.